<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>CEFACLORÂ - cefaclorÂ capsuleÂ </strong><br>PD-Rx Pharmaceuticals, Inc.<br></p></div>
<h1>CEFACLOR CAPSULES, USP<br>Â <br>Rx only</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_86320f82-a0a3-c121-910a-4d9264a27e29"></a><a name="section-1"></a><p></p>
<h1></h1>
<p class="First">To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefaclorÂ and other antibacterial drugs, cefaclorÂ should be used only to treat or prevent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that are proven or strongly suspected to be caused by bacteria.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="LINK_f9347756-7309-0b78-7759-e57e3a7c4043"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Cefaclor is a semisynthetic cephalosporin antibiotic for oral administration. It is chemically designated as 3-chloro-7-D-(2-phenylglycinamido)-3-cephem-4-carboxylic acid monohydrate. The molecular formula for cefaclor is C<span class="Sub">15</span>H<span class="Sub">14</span>ClN<span class="Sub">3</span>O<span class="Sub">4</span>Sâ€¢H<span class="Sub">2</span>O and the molecular weight is 385.82.</p>
<div class="Figure">
<img alt="Molecular formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b093ec49-da83-40e3-8e1c-8a64b7f45d27&amp;name=cefaclor-1.jpg"><p class="MultiMediaCaption">Molecular formula</p>
</div>
<p>Each capsule contains cefaclor monohydrate equivalent to 250 mg (0.68 mmol) or 500 mg (1.36 mmol) anhydrous cefaclor. The capsules also contain black iron oxide,Â croscarmellose sodium, FD&amp;C Red No. 3, FD&amp;C Blue No. 2, gelatin, magnesium stearate, corn starch, and titanium dioxide.</p>
<p>The color of the capsule powder is white to off white.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="LINK_06020f4c-713e-6487-653f-c481dd448699"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Cefaclor is well absorbed after oral administration to fasting subjects. Total absorption is the same whether the drug is given with or without food; however, when it is taken with food, the peak concentration achieved is 50% to 75% of that observed when the drug is administered to fasting subjects and generally appears from three fourths to 1 hour later.Â Following administration of 250- mg, 500-mg, and 1-g doses to fasting subjects, average peak serum levels of approximately 7, 13, and 23 mcg/mL respectively were obtained within 30 to 60 minutes. Approximately 60% to 85% of the drug is excreted unchanged in the urine within 8 hours, the greater portion being excreted within the first 2 hours. During this 8-hour period, peak urine concentrations following the 250-mg, 500-mg, and 1-g doses were approximately 600, 900, and 1,900 mcg/mL, respectively. The serum half-life in normal subjects is 0.6 to 0.9 hour. In patients with reduced renal function, the serum half-life of cefaclor is slightly prolonged. In those with complete absence of renal function, the plasma half-life of the intact molecule is 2.3 to 2.8 hours. Excretion pathways in patients with markedly <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span> have not been determined. Hemodialysis shortens the half-life by 25% to 30%.</p>
<div class="Section" data-sectionCode="34090-1">
<a name="LINK_87f874d2-1cf6-e7fc-73cb-f7c02984c077"></a><a name="section-3.1"></a><p></p>
<h2><span class="Italics">Microbiology</span></h2>
<p class="First"><span class="Italics">In vitro </span>tests demonstrate that the bactericidal action of the cephalosporins results from inhibition of cell-wall synthesis. Cefaclor has been shown to be active against most <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the following microorganisms, both <span class="Italics">in vitro </span>and in clinical <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> as described in the <a href="#LINK_2ccfc88f-b1d2-c1ad-9dbf-e7069ae147cc">INDICATIONS AND USAGEÂ </a>section.</p>
<p>Aerobes, Gram-positive<br>Staphylococci, including coagulase-positive, coagulase-negative, and penicillinase-producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span><br><span class="Italics">Streptococcus pneumoniae<br></span><span class="Italics">Streptococcus pyogenes </span>(group A Î²-hemolytic streptococci)</p>
<p>Aerobes, Gram-negative<br><span class="Italics">Escherichia coli<br></span><span class="Italics">Haemophilus influenzae</span>, excluding Î²-lactamase-negative, ampicillin-resistant <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span><br><span class="Italics">Klebsiella spp.<br></span><span class="Italics">Proteus mirabilis</span></p>
<p>The following <span class="Italics">in vitro </span>data are available, <span class="Bold"><span class="Underline">but their clinical significance is unknown. </span></span></p>
<p>Cefaclor exhibits <span class="Italics">in vitro </span>minimal inhibitory concentrations (MICs) of <span class="Underline">&lt;</span> 8 mcg/mL against most (<span class="Underline">&gt;</span> 90%) <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the following microorganisms; however, the safety and effectiveness of cefaclor in treating clinical <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> due to these microorganisms have not been established in adequate and well-controlled clinical trials.</p>
<p>Aerobes, Gram-negative<br><span class="Italics">Citrobacter diversus<br></span><span class="Italics">Moraxella (Branhamella) catarrhalis<br></span><span class="Italics">Neisseria gonorrhoeae</span></p>
<p>Anaerobes, Gram-positive<br><span class="Italics">Bacteroides </span>spp (excluding <span class="Italics">Bacteroides fragilis</span>)<br><span class="Italics">Peptococcus<br></span><span class="Italics">Peptostreptococcus<br></span><span class="Italics">Propionibacterium <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acnes</span></span></p>
<p><span class="Italics">Note: Pseudomonas spp</span>., <span class="Italics">Acinetobacter calcoaceticus </span>and most <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">enterococci </span>(<span class="Italics">Enterococcus faecalis</span>, group D streptococci), <span class="Italics">Enterobacter spp</span>., indole-positive <span class="Italics">Proteus</span>, <span class="Italics">Morganella morganii </span>(formerly <span class="Italics">Proteus </span>morganii), <span class="Italics">Provendencia rettgeri </span>(formerly <span class="Italics">Proteus </span>rettgeri), andÂ <span class="Italics">Serratia spp</span>. are resistant to cefaclor. When tested by <span class="Italics">in vitro </span>methods, staphylococci exhibit cross-resistance between cefaclor and methicillin-type antibiotics.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="LINK_dce27382-d872-af3b-4fd6-e44864739954"></a><a name="section-3.2"></a><p></p>
<h2>Susceptibility Testing</h2>
<p class="First"><span class="Bold">Dilution Techniques</span> â€” Quantitative methods that are used to determine <span class="product-label-link" type="condition" conceptid="4190299" conceptname="Broth microdilution susceptibility test">minimum inhibitory concentrations</span> (MIC) provide reproducible estimates of the susceptibility of bacteria to antimicrobial compounds. One such standardized procedure that has been recommended for use with cefaclor powder uses a standardized dilution method<span class="Sup">1</span> (broth, agar, or microdilution). The MIC values obtained should be interpreted according to the following criteria:</p>
<a name="ibaffeb56-be3f-454e-80fb-80151ce3af96"></a><table border="1" frame="border">
<col>
<col>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule" align="center">Â <span class="Underline">MIC (mcg/mL)</span>
</td>
<td class="Botrule Rrule" align="center">Â <span class="Underline">Interpretation*</span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center">Â <span class="Underline">&lt;</span> 8</td>
<td class="Botrule Rrule" align="center">Â Susceptible (S)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center">Â 16</td>
<td class="Botrule Rrule" align="center">Â Intermediate (I)</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="center">Â <span class="Underline">&gt;</span> 32</td>
<td class="Botrule Rrule" align="center">Â Resistant (R)</td>
</tr>
</tbody>
</table>
<p>*When testing <span class="Italics">H. influenzae </span>spp. these interpretive standards are applicable only to broth microdilution method using Haemophilus Test Medium (HTM)<span class="Sup">1</span></p>
<p><span class="Bold"><span class="Italics">Note:</span></span> Î²-lactamase-negative, ampicillin-resistant <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">H. influenzae </span>should be considered resistant to cefaclor despite apparent <span class="Italics">in vitro </span>susceptibility to this agent.</p>
<p>A report of â€œSusceptibleâ€? indicates that the pathogen is likely to be inhibited by usually achievable concentrations of the antimicrobial compound in blood. A report of â€œIntermediateâ€? indicates that the result should be considered equivocal, and, if the microorganism is not fully susceptible to alternative, clinically feasible drugs, the test should be repeated. This category implies possible clinical applicability in body sites where the drug is physiologically concentrated or in situations where high dosage of drug can be used. This category also provides a buffer zone that prevents small uncontrolled technical factors from causing major discrepancies in interpretation. A report of â€œResistantâ€? indicates that usually achievable concentrations of the antimicrobial compound in the blood are unlikely to be inhibitory and that other therapy should be selected.</p>
<p>Standardized susceptibility test procedures require the use of laboratory control microorganisms. Standard cefaclor powder should provide the following MIC values:</p>
<a name="ic597b446-328d-44db-8a2e-e9b51b596da8"></a><table border="1" frame="border">
<col>
<col>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule" align="center">Â <span class="Underline">Microorganism</span>
</td>
<td class="Botrule Rrule" align="center">Â <span class="Underline">MIC (mcg/mL)</span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center">Â <span class="Italics">E. coli</span> ATCC 25922</td>
<td class="Botrule Rrule" align="center">Â 1Â - 4</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center">Â <span class="Italics">E. faecalis</span> ATCC 29212</td>
<td class="Botrule Rrule" align="center">Â &gt; 32</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="center">Â <span class="Italics">S. aureus</span> ATCC 29213</td>
<td class="Botrule Rrule" align="center">Â 1Â - 4</td>
</tr>
</tbody>
</table>
<p>When testing <span class="Italics">H. influenzae*</span></p>
<a name="if6674806-d49a-4407-878c-5c698637099d"></a><table border="1" frame="border">
<col>
<col>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule" align="center">Â <span class="Underline">Microorganism</span>
</td>
<td class="Botrule Rrule" align="center">Â <span class="Underline">MIC (mcg/mL)</span>
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule">Â <span class="Italics">H. influenzae</span> ATCC 49766</td>
<td class="Botrule Rrule">Â Â Â Â Â  1 - 4</td>
</tr>
</tbody>
</table>
<p>*Broth microdilution test performed using Haemophilus Test Medium (HTM)<span class="Sup">1</span></p>
<p><span class="Bold">Diffusion Techniques</span>â€” Quantitative methods that require measurement of zone diameters provide reproducible estimates of the susceptibility of bacteria to antimicrobial compounds. One such standardized procedure<span class="Sup">2</span> that has been recommended for use with disks to test the susceptibility of microorganisms to cefaclor uses the 30 mcg cefaclor disk. Interpretation involves correlation of the diameter obtained in the disk test with the MIC for cefaclor. Reports from the laboratory providing results of the standard single-disk susceptibility test with a 30 mcg cefaclor disk should be interpreted according to the following criteria:</p>
<p>When Testing Organisms Other Than <span class="Italics">Haemophilus </span>spp. and Streptococci</p>
<a name="i7ed359d6-3cc5-4e5a-83e6-27513099ae68"></a><table border="1" frame="border">
<col>
<col>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule" align="center" valign="top">Â <span class="Underline">Zone Diameter (mm)</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">Â <span class="Underline">Interpretation</span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top">Â <span class="Underline">&gt;</span> 18</td>
<td class="Botrule Rrule" align="center" valign="top">Â Susceptible (S)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top">Â 15 - 17</td>
<td class="Botrule Rrule" align="center" valign="top">Â Intermediate (I)</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="center" valign="top">Â <span class="Underline">&lt;</span> 14</td>
<td class="Botrule Rrule" align="center" valign="top">Â Resistant (R)</td>
</tr>
</tbody>
</table>
<p>When testing <span class="Italics">H. influenzae</span>*</p>
<a name="i282f9b29-ffd8-4463-8a25-886359e33a02"></a><table border="1" frame="border">
<col>
<col>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule" align="center">Â <span class="Underline">Zone Diameter (mm)</span>
</td>
<td class="Botrule Rrule" align="center">Â <span class="Underline">Interpretation</span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center">Â <span class="Underline">&gt;</span> 20</td>
<td class="Botrule Rrule" align="center">Â Susceptible (S)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center">Â 17 - 19</td>
<td class="Botrule Rrule" align="center">Â Intermediate (I)</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="center">Â <span class="Underline">&lt;</span> 16</td>
<td class="Botrule Rrule" align="center">Â Resistant (R)</td>
</tr>
</tbody>
</table>
<p>*Disk susceptibility test performed using Haemophilus Test Medium (HTM)<span class="Sup">2</span></p>
<p><span class="Bold">Note:</span> Î²-lactamase-negative, ampicillin-resistant <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">H. influenzae </span>should be considered resistant to cefaclor despite apparent <span class="Italics">in vitro </span>susceptibility to this agent.</p>
<p>Interpretation should be as stated above for results using dilution techniques.</p>
<p>As with standard dilution techniques, diffusion methods require the use of laboratory control microorganisms. The 30 mcg cefaclor disk should provide the following zone diameters in these laboratory test quality control <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>:</p>
<a name="i7c738280-a105-495b-85b3-7d3ce0dcc0a9"></a><table border="1" frame="border">
<col>
<col>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule" align="center" valign="top">Â <span class="Underline">Microorganisms</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">Â <span class="Underline">Zone Diameter (mm)</span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top">Â <span class="Italics">E. coli</span> ATCC 25922</td>
<td class="Botrule Rrule" align="center" valign="top">Â 23 - 27</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="center" valign="top">Â <span class="Italics">S. aureus</span> ATCC 25923</td>
<td class="Botrule Rrule" align="center" valign="top">Â 27 - 31</td>
</tr>
</tbody>
</table>
<p>When testing <span class="Italics">H. influenzae</span>*</p>
<a name="ic88fa585-0c59-4fe1-8bfb-2490f1f521f3"></a><table border="1" frame="border">
<col>
<col>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule" align="center" valign="top">Â <span class="Underline">Microorganisms</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">Â <span class="Underline">Zone Diameter (mm)</span>
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="center" valign="top">Â <span class="Italics">H. influenzae</span> ATCC 49766</td>
<td class="Botrule Rrule" align="center" valign="top">Â 25 - 31</td>
</tr>
</tbody>
</table>
<p>*Disk susceptibility test performed using Haemophilus Test Medium (HTM)<span class="Sup">2</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="LINK_2ccfc88f-b1d2-c1ad-9dbf-e7069ae147cc"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">Cefaclor is indicated in the treatment of the following <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> when caused by susceptible <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the designated microorganisms:</p>
<p><span class="Underline"><span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">Otitis media</span></span> caused by <span class="Italics">Streptococcus pneumoniae, Haemophilus influenzae</span>, staphylococci, and <span class="Italics">Streptococcus pyogenes</span></p>
<p><span class="Bold">Note:</span> Î²-lactamase-negative, ampicillin-resistant (BLNAR) <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">Haemophilus influenzae </span>should be considered resistant to cefaclor despite apparent <span class="Italics">in vitro </span>susceptibility of some BLNAR <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>.</p>
<p><span class="Underline"><span class="product-label-link" type="condition" conceptid="4175297" conceptname="Lower respiratory tract infection">Lower respiratory tract infections</span></span>, including <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> caused by <span class="Italics">Streptococcus pneumoniae, Haemophilus influenzae</span>, and <span class="Italics">Streptococcus pyogenes.</span></p>
<p><span class="Bold">Note:</span> Î²-lactamase-negative, ampicillin-resistant (BLNAR) <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">Haemophilus influenzae </span>should be considered resistant to cefaclor despite apparent <span class="Italics">in vitro </span>susceptibility of some BLNAR <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>.</p>
<p><span class="Underline"><span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">Pharyngitis</span> and <span class="product-label-link" type="condition" conceptid="4234533" conceptname="Tonsillitis">Tonsillitis</span></span>, caused by <span class="Italics">Streptococcus pyogenes</span></p>
<p><span class="Italics">Note</span>: Penicillin is the usual drug of choice in the treatment and prevention of <span class="product-label-link" type="condition" conceptid="437779" conceptname="Streptococcal infectious disease">streptococcal infections</span>, including the prophylaxis of <span class="product-label-link" type="condition" conceptid="442313" conceptname="Rheumatic fever">rheumatic fever</span>. Cefaclor is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cefaclor in the subsequent prevention of <span class="product-label-link" type="condition" conceptid="442313" conceptname="Rheumatic fever">rheumatic fever</span> are not available at present.</p>
<p><span class="Underline"><span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary tract infections</span></span>, including <span class="product-label-link" type="condition" conceptid="198199" conceptname="Pyelonephritis">pyelonephritis</span> and <span class="product-label-link" type="condition" conceptid="195588" conceptname="Cystitis">cystitis</span>, caused by <span class="Italics">Escherichia coli, Proteus mirabilis, Klebsiella </span>spp., and coagulase-negative staphylococci</p>
<p><span class="Underline">Skin and skin structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span></span> caused by <span class="Italics">Staphylococcus aureus </span>and <span class="Italics">Streptococcus pyogenes</span></p>
<p>Appropriate culture and susceptibility studies should be performed to determine susceptibility of the causative organism to cefaclor.</p>
<p>To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefaclor and other antibacterial drugs, cefaclorÂ should be used only to treat or prevent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="LINK_5cfa357d-fca3-f952-d4e6-461f1736a04f"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Cefaclor is contraindicated in patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy</span> to the cephalosporin group of antibiotics.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="LINK_2e6bb69a-78db-83e1-cf98-0545f89dcceb"></a><a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<p class="First"><span class="Bold">BEFORE THERAPY WITH CEFACLOR IS INSTITUTED, CAREFUL INQUIRY SHOULD BE MADE TO DETERMINE WHETHER THE PATIENT HAS HAD PREVIOUS <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">HYPERSENSITIVITY REACTIONS</span> TO CEFACLOR, CEPHALOSPORINS, PENICILLINS, OR OTHER DRUGS. IF THIS PRODUCT IS TO BE GIVEN TO PENICILLIN-SENSITIVE PATIENTS, CAUTION SHOULD BE EXERCISED BECAUSE CROSS-<span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">HYPERSENSITIVITY</span> AMONG Î²-LACTAM ANTIBIOTICS HAS BEEN CLEARLY DOCUMENTED AND MAY OCCUR IN UP TO 10% OF PATIENTS WITH A HISTORY OF <span class="product-label-link" type="condition" conceptid="439224" conceptname="Drug allergy">PENICILLIN ALLERGY</span>.</span></p>
<p><span class="Bold">IF AN <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">ALLERGIC REACTION</span> TO CEFACLOR OCCURS, DISCONTINUE THE DRUG. SERIOUS ACUTE <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">HYPERSENSITIVITY REACTIONS</span> MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED.</span></p>
<p>Antibiotics, including cefaclor, should be administered cautiously to any patient who has demonstrated some form of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy</span>, particularly to drugs.</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">Pseudomembranous colitis</span> has been reported with nearly all antibacterial agents, including cefaclor, and has ranged in severity from mild to life-threatening. Therefore, it is important to consider this diagnosis in patients who present with <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> subsequent to the administration of antibacterial agents.</span></p>
<p>Treatment with antibacterial agents alters the normal flora of the colon and may permit overgrowthof clostridia. Studies indicate that a toxin produced by <span class="Italics">Clostridium difficile </span>is one primary cause of antibiotic-associated <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>.</p>
<p>After the diagnosis of <span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">pseudomembranous colitis</span> has been established, therapeutic measures should be initiated. Mild cases of <span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">pseudomembranous colitis</span> usually respond to drug discontinuation alone. In moderate to severe cases, consideration should be given to management with fluids and electrolytes, protein supplementation and treatment with an antibacterial drug effective against <span class="Italics">C. difficile.</span></p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="LINK_902a9654-2f5b-9050-b666-1d40b44f9553"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42232-9">
<a name="LINK_b92de18d-27b8-815e-e083-99b4b85d7218"></a><a name="section-7.1"></a><p></p>
<h2>General</h2>
<p class="First">Prescribing cefaclorÂ in the absence of a proven or strongly suspected <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span> or a <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.</p>
<p>Prolonged use of cefaclor may result in the overgrowth of nonsusceptible organisms. Careful observation of the patient is essential. If <span class="product-label-link" type="condition" conceptid="4105019" conceptname="Superimposed infection">superinfection</span> occurs during therapy, appropriate measures should be taken.</p>
<p>Positive direct Coombsâ€™ tests have been reported during treatment with the cephalosporin antibiotics. It should be recognized that a positive Coombsâ€™ test may be due to the drug, e.g., in hematologic studies or in transfusion cross-matching procedures when antiglobulin tests are performed on the minor side or in Coombsâ€™ testing of newborns whose mothers have received cephalosporin antibiotics before parturition.</p>
<p>Cefaclor should be administered with caution in the presence of markedly <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. Since the half-life of cefaclor in <span class="product-label-link" type="condition" conceptid="4090272" conceptname="Anuria">anuria</span> is 2.3 to 2.8 hours, dosage adjustments for patients with moderate or severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> are usually not required. Clinical experience with cefaclor under such conditions is limited; therefore, careful clinical observation and laboratory studies should be made.</p>
<p>As with other Î²-lactam antibiotics, the renal excretion of cefaclor is inhibited by probenecid. Antibiotics, including cephalosporins, should be prescribed with caution in individuals with a history of gastrointestinal disease, particularly <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="LINK_2f5ec83c-34ef-b3fb-81d0-a0561c94a483"></a><a name="section-7.2"></a><p></p>
<h2>Information for Patients</h2>
<p class="First">Patients should be counseled that antibacterial drugs including cefaclor should only be used to treat <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infections</span>. They do not treat <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infections</span> (e.g., the <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">common cold</span>). When cefaclor is prescribed to treat a <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span>, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by cefaclor or other antibacterial drugs in the future.</p>
</div>
<div class="Section" data-sectionCode="34074-5">
<a name="LINK_a02acc57-da93-e121-3881-85cb627d2839"></a><a name="section-7.3"></a><p></p>
<h2>Drug /Laboratory Test Interactions</h2>
<p class="First">Patients receiving cefaclor may show a false-positive reaction for glucose in the urine with tests that use Benedictâ€™s and Fehlingâ€™s solutions and also with Clinitest<span class="Sup">Â®</span> tablets.</p>
<p>There have been reports of increased anticoagulant effect when cefaclor and oral anticoagulants were administered concomitantly.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="LINK_499189d7-eaf3-a52d-656d-e60b681610ca"></a><a name="section-7.4"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Studies have not been performed to determine potential for carcinogenicity, mutagenicity, or impairment of fertility.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="LINK_34d90e01-c88c-a7c1-a76e-a7900102f98a"></a><a name="section-7.5"></a><p></p>
<h2>Pregnancyâ€“Teratogenic Effectsâ€“Pregnancy Category B</h2>
<p class="First">Reproduction studies have been performed in mice and rats at doses up to 12 times the human dose and in ferrets given 3 times the maximum human dose and have revealed no harm to the fetus due to cefaclor. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.</p>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="LINK_3706b442-4481-d6c9-f97a-30752ed22d4e"></a><a name="section-7.6"></a><p></p>
<h2>Labor and Delivery</h2>
<p class="First">The effect of cefaclor on labor and delivery is unknown.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="LINK_781652ae-3fbb-3087-976c-d77cac387086"></a><a name="section-7.7"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">Small amounts of cefaclor have been detected in motherâ€™s milk following administration of single 500 mg doses. Average levels were 0.18, 0.20, 0.21, and 0.16 mcg/mL at 2, 3, 4, and 5 hours respectively. Trace amounts were detected at 1 hour. The effect on nursing infants is not known. Caution should be exercised when cefaclor is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="LINK_086364f4-15db-d7f7-6801-4708e5a37e25"></a><a name="section-7.8"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">Safety and effectiveness of this product for use in infants less than 1 month of age have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="LINK_e5b47c21-e965-f97a-19cd-7b24b197c661"></a><a name="section-7.9"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">Of the 3703 patients in clinical studies of cefaclor, 594 (16.0%) were 65 and older. No overall differences in safety or effectiveness were observed between these subjects and younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.</p>
<p>This drug is known to be substantially excreted by the kidney (<span class="Italics">see </span><span class="Bold"><a href="#LINK_06020f4c-713e-6487-653f-c481dd448699">CLINICAL PHARMACOLOGY</a></span>), and the risk of toxic reactions to this drug may be greater in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function (see <span class="Bold"><a href="#LINK_ba9c2657-7d2c-38cf-5afb-933d0b1d26c1">DOSAGE AND ADMINISTRATION</a></span>).</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="LINK_6fc696e2-86f9-28c4-a2a2-9f18e747a4a8"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">Adverse effects considered to be related to therapy with cefaclor are listed below:</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> </span>reactions have been reported in about 1.5% of patients and include <span class="product-label-link" type="condition" conceptid="4083309" conceptname="Morbilliform eruption">morbilliform eruptions</span> (1 in 100). <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, and positive Coombsâ€™ tests each occur in less than 1 in 200 patients.</p>
<p>Cases of <span class="Bold">serum-sickness-like </span>reactions have been reported with the use of cefaclor. These are characterized by findings of <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rashes</span>, and other skin manifestations accompanied by <span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">arthritis</span>/<span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, with or without <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, and differ from classic <span class="product-label-link" type="condition" conceptid="432522" conceptname="Transfusion reaction due to serum protein reaction">serum sickness</span> in that there is infrequently associated <span class="product-label-link" type="condition" conceptid="315085" conceptname="Lymphadenopathy">lymphadenopathy</span> and <span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">proteinuria</span>, no circulating immune complexes, and no evidence to date of sequelae of the reaction. Occasionally, solitary symptoms may occur, but do not represent a <span class="Bold">serum-sickness-like </span>reaction. While further investigation is ongoing, <span class="Bold">serum-sickness-like </span>reactions appear to be due to <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> and more often occur during or following a second (or subsequent) course of therapy with cefaclor. Such reactions have been reported more frequently in pediatric ptients than in adults with an overall occurrence ranging from 1 in 200 (0.5%) in one focused trial to 2 in 8,346 (0.024%) in overall clinical trials (with an incidence in pediatric patients in clinical trials of 0.055%) to 1 in 38,000 (0.003%) in spontaneous event reports. Signs and symptoms usually occur a few days after initiation of therapy and subside within a few days after cessation of therapy; occasionally these reactions have resulted in hospitalization, usually of short duration (median hospitalization = 2 to 3 days, based on postmarketing surveillance studies). In those requiring hospitalization, the symptoms have ranged from mild to severe at the time of admission with more of the severe reactions occurring in pediatric patients. Antihistamines and glucocorticoids appear to enhance resolution of the signs and symptoms. No serious sequelae have been reported.</p>
<p>More severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span>, including <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>, and <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> have been reported rarely. Anaphylactoid events may be manifested by solitary symptoms, including <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> (including face and limbs), <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesias</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, or <span class="product-label-link" type="condition" conceptid="4237053" conceptname="Vasodilatation">vasodilatation</span>. <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylaxis</span> may be more common in patients with a history of <span class="product-label-link" type="condition" conceptid="439224" conceptname="Drug allergy">penicillin allergy</span>.</p>
<p>Rarely, <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> symptoms may persist for several months.</p>
<p><span class="Italics">Gastrointestinal </span>symptoms occur in about 2.5% of patients and include <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (1 in 70).</p>
<p>Onset of <span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">pseudomembranous colitis</span> symptoms may occur during or after antibiotic treatment (<span class="Italics">see </span><span class="Bold"><a href="#LINK_2e6bb69a-78db-83e1-cf98-0545f89dcceb">WARNINGS</a></span>). <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> have been reported rarely. As with some penicillins and some other cephalosporins, transient <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> and <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">cholestatic jaundice</span> have been reported rarely.</p>
<p><span class="Italics">Other </span>effects considered related to therapy included <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span> (1 in 50 patients), <span class="product-label-link" type="condition" conceptid="4146239" conceptname="Pruritus of genital organs">genital pruritus</span> , <span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">moniliasis</span> or <span class="product-label-link" type="condition" conceptid="4081648" conceptname="Acute vaginitis">vaginitis</span> (aboutÂ 1 in 50 patients), and, rarely, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> or reversible interstitial <span class="product-label-link" type="condition" conceptid="193253" conceptname="Nephritis">nephritis</span>.</p>
<p><span class="Italics">Causal Relationship Uncertainâ€“</span></p>
<p><span class="Italics">CNSâ€“</span>Rarely, reversible <span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">hyperactivity</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="4208994" conceptname="Increased muscle tone">hypertonia</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, and <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> have been reported.</p>
<p>Transitory abnormalities in clinical laboratory test results have been reported. Although they were of uncertain etiology, they are listed below to serve as alerting information for the physician.</p>
<p><span class="Italics">Hepaticâ€“</span>Slight elevations of AST, ALT, or alkaline phosphatase values (1 in 40).</p>
<p><span class="Italics">Hematopoieticâ€“</span>As has also been reported with other Î²-lactam antibiotics, transient <span class="product-label-link" type="condition" conceptid="320074" conceptname="Lymphocytosis">lymphocytosis</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, and, rarely, <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span>, <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span>, <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>, and reversible <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> of possible clinical significance.</p>
<p>There have been rare reports of increased <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time with or without clinical <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> in patients receiving cefaclor and warfarin concomitantly.</p>
<p><span class="Italics">Renalâ€“ </span>Slight elevations in BUN or serum creatinine (less than 1 in 500) or abnormal urinalysis (less than 1 in 200).</p>
<div class="Section" data-sectionCode="34084-4">
<a name="LINK_e210a904-3a92-bd58-872f-c2032bfc5769"></a><a name="section-8.1"></a><p></p>
<h2>Cephalosporin-class Adverse Reactions</h2>
<p class="First">In addition to the adverse reactions listed above that have been observed in patients treated with cefaclor, the following adverse reactions and altered laboratory tests have been reported for cephalosporin-class antibiotics: <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="4105019" conceptname="Superimposed infection">superinfection</span>, renal dysfunction, <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">toxic nephropathy</span>, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>, false positive test for urinary glucose, elevated bilirubin, elevated LDH, and <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span>.</p>
<p>Several cephalosporins have been implicated in triggering <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, particularly in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> when the dosage was not reduced. If <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> associated with drug therapy occur, the drug should be discontinued. Anticonvulsant therapy can be given if clinically indicated (<span class="Italics">see </span><span class="Bold"><a href="#LINK_ba9c2657-7d2c-38cf-5afb-933d0b1d26c1">DOSAGE AND ADMINISTRATIONÂ </a></span>andÂ <span class="Bold"><a href="#LINK_62549fa6-eb0c-1f1e-9d93-03f20617c664">OVERDOSAGE</a></span>Â sections).</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="LINK_62549fa6-eb0c-1f1e-9d93-03f20617c664"></a><a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First"><span class="Italics">Signs and Symptoms â€“</span>The toxic symptoms following an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> of cefaclor may include <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">epigastric distress</span>, and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>. The severity of the <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">epigastric distress</span> and the <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> are dose related. If other symptoms are present, it is probable that they are secondary to an underlying disease state, an <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>, or the effects of other <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">intoxication</span>.</p>
<p><span class="Italics">Treatment</span>â€“To obtain up-to-date information about the treatment of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, a good resource is your certified Regional Poison Control Center. Telephone numbers of certified poison control centers are listed in the <span class="Italics">Physiciansâ€™ Desk Reference (PDR)</span>. In managing overdosage, consider the possibility of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">multiple drug overdoses</span>, interaction among drugs, and unusual drug kinetics in your patient.</p>
<p>Unless 5 times the normal dose of cefaclor has been ingested, gastrointestinal decontamination will not be necessary.</p>
<p>Protect the patientâ€™s airway and support ventilation and perfusion. Meticulously monitor and maintain, within acceptable limits, the patientâ€™s vital signs, blood gases, serum electrolytes, etc. Absorption of drugs from the gastrointestinal tract may be decreased by giving activated charcoal, which, in many cases, is more effective than <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span> or lavage; consider charcoal instead of or in addition to gastric emptying. Repeated doses of charcoal over time may hasten elimination of some drugs that have been absorbed. Safeguard the patientâ€™s airway when employing gastric emptying or charcoal.</p>
<p>Forced <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span>, peritoneal dialysis, hemodialysis, or charcoal hemoperfusion have not been established as beneficial for an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> of cefaclor.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="LINK_ba9c2657-7d2c-38cf-5afb-933d0b1d26c1"></a><a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">Cefaclor is administered orally.</p>
<p><span class="Italics">Adults </span>â€“The usual adult dosage is 250 mg every 8 hours. For more severe <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> (such as <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>) or those caused by less susceptible organisms, doses may be doubled.</p>
<p><span class="Italics">Pediatric patients</span>â€“The usual recommended daily dosage for pediatric patients is 20 mg/kg/day in divided doses every 8 hours. In more serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">otitis media</span>, and <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> caused by less susceptible organisms, 40 mg/kg/day are recommended, with a maximum dosage of 1 g/day.</p>
<p>Cefaclor may be administered in the presence of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. Under such a condition, the dosage usually is unchanged (<span class="Italics">see </span><span class="Bold"><a href="#LINK_902a9654-2f5b-9050-b666-1d40b44f9553">PRECAUTIONS</a></span>).</p>
<p>In the treatment of Î²-hemolytic <span class="product-label-link" type="condition" conceptid="437779" conceptname="Streptococcal infectious disease">streptococcal infections</span>, a therapeutic dosage of cefaclor should be administered for at least 10 days.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="LINK_f23204b1-0672-1cd8-e10c-380eac252b12"></a><a name="section-11"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Capsules:<br>Cefaclor Capsules, USP 250 mg: opaque purple and white hard gelatin capsules imprinted with "West Ward 985" in bottles of 15 and bottles of 100.<br>Cefaclor Capsules, USP 500 mg: opaque purple and gray hard gelatin capsules imprinted with "West Ward 986" in bottles of 15 and bottles of 100.Â </p>
<p>Store bottles at 20Â° to 25Â°C (68Â° to 77Â° F). [See USP Controlled Room Temperature]</p>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="LINK_4a5a501b-a1f1-1b68-2d21-e354df93e35d"></a><a name="section-12"></a><p></p>
<h1>REFERENCES</h1>
<p class="First">1. National Committee for Clinical Laboratory Standards. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically - Fourth Edition. Approved Standard NCCLS Document M7-A4, Vol. 17, No. 2, NCCLS, Wayne, PA, January 1997.<br>2. National Committee for Clinical Laboratory Standards. Performance Standards for Antimicrobial Disk Susceptibility Test - Sixth Edition, Approved Standard NCCLS Document M2-A6, Vol. 17, No. 1, NCCLS, Wayne, PA, January 1997.</p>
<p>West-ward Pharmaceutical Corp.<br>Eatontown, NJ 07724 - USA<br>Distributor</p>
<p>Manufactured by:<br>Jazeera Pharmaceutical Industries (JPI)<br>Al- Kharj Road<br>P.O. Box 106229<br>Riyadh 11666<br>Saudi Arabia</p>
<p>An Affiliate of:<br>Hikma Pharmaceuticals<br>P.O. Box 182400<br>Amman 11118<br>Jordan</p>
<p>Rev.: July 2006</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="LINK_8aa7a5b2-e0a5-4711-a2b6-1c83599f14d8"></a><a name="section-13"></a><p></p>
<h1>Principal Display Panel</h1>
<br><br><div class="Figure"><img alt="43063194 label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b093ec49-da83-40e3-8e1c-8a64b7f45d27&amp;name=43063194.jpg"></div>
<br>PDRx Label<br><p class="First"><br></p>
<p><br></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>CEFACLORÂ 		
					</strong><br><span class="contentTableReg">cefaclor capsule</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:43063-194(NDC:0143-9986)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>CEFACLOR</strong> (CEFACLOR) </td>
<td class="formItem">CEFACLOR</td>
<td class="formItem">500Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C BLUE NO. 2</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C RED NO. 3</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>GELATIN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FERROSOFERRIC OXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">PURPLE,Â GRAY</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE</td>
<td class="formLabel">Size</td>
<td class="formItem">23mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">WestWard;986</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:43063-194-30</td>
<td class="formItem">30  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA065350</td>
<td class="formItem">05/01/2007</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>PD-Rx Pharmaceuticals, Inc.
							(156893695)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant -Â </span>PD-Rx Pharmaceuticals, Inc. (156893695)</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">PD-Rx Pharmaceuticals, Inc.</td>
<td class="formItem"></td>
<td class="formItem">156893695</td>
<td class="formItem">repack</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 9/2009<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>478954c4-aa48-49ff-a680-f756d95182bd</div>
<div>Set id: b093ec49-da83-40e3-8e1c-8a64b7f45d27</div>
<div>Version: 2</div>
<div>Effective Time: 20090928</div>
</div>
</div>Â <div class="DistributorName">PD-Rx Pharmaceuticals, Inc.</div></p>
</body></html>
